Your 25-second video preview has ended.
to continue watching, please Log In or Register:
Findings From a Phase 2 Clinical Trial of ECT
Szilárd Kiss, MD, discusses results from a phase 2 multicenter trial that compared encapsulated cell technology (ECT; NT-503-3) with aflibercept (Eylea, Regeneron) in patients who were not treatment-naïve. According to Dr. Kiss, the implanted cells did not work as well as they did in the preclinical animal trials. The phase 2 trial was terminated early due to the number of rescue injections needed. For patients with wet AMD, there is still hope that this technology may prove to be a long-term delivery mechanism for patients who need repeated intravitreal injections.